FDA approve Dymista (Meda AB) for Seasonal Allergic Rhinitis

The FDA has approved Dymista, from Meda AB, for treatment of Seasonal Allergic Rhinitis. The efficacy and safety of Dymista has been documented in several studies involving over 4,000 patients, including a long-term safety study with more than 600 patients. Dymista will be available in the US during the second half of 2012. The treatment was filed for marketing approval in Europe in October 2011.